Flexible and agile biotech with a focus on Oncology and AI
Leveraging AI and data insights to expedite and improve decision making around licensing and development of drug candidates. AI unlocks the hidden value of drug candidates licensed from biopharma to achieve accelerated, optimized and de-risked clinical development.
Oncoteq was founded in 2022 by Cureteq, an asset-manager and company builder engaged in founding and seeding biotechs anchored around a disease area or technology platform. Oncoteq is in a period of transition to a fully independent biotech company while maintaining its lean and agile approach.
The power of the AI platform
- Scans 95 % of the world wide web
- Crawls up to 10 billion web pages per day in real-time
- Extracts structured information from PDFs, images, graphs and more
- Understands life science context, language and biological concepts, i.e., ontology, for data extraction and processing
The AI platform
The AI platform analyses approximately 95% of all publically available and published data such as literature databases, molecular structures, patents, genetic databases, safety databases and much more. This ensures a complete, systematic and unbiased analysis that helps identify the most valuable and safe use of a given drug candidate based on its design and attributes. The AI platform processes much more data than humans can and differentiates from other AI approaches through proprietary capabilities in Life Science Language Processing™ and Computer Vision to contextualise multimodal data and discover non-obvious connections. Taken together, this greatly enhances the effectiveness and impact of the AI analyses. Oncoteq utilises this powerful AI engine within its strategic partnership with Innoplexus, a sister company.
For setting up meeting at J.P. Morgan 2024, San Francisco
